Clinical Trials Directory

Trials / Completed

CompletedNCT01583738

Effect of V0251 in Acute Vertigo

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
132 (actual)
Sponsor
Pierre Fabre Medicament · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.

Conditions

Interventions

TypeNameDescription
DRUGV0251single dose
DRUGplacebosingle dose

Timeline

Start date
2012-04-01
Primary completion
2013-04-01
Completion
2013-04-01
First posted
2012-04-24
Last updated
2014-10-30

Locations

40 sites across 5 countries: Czechia, France, Germany, Hungary, Spain

Source: ClinicalTrials.gov record NCT01583738. Inclusion in this directory is not an endorsement.